Farallon Capital Management LLC Gilead Sciences, Inc. Transaction History

Farallon Capital Management LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Nov 14, 2018	SELL	$71.28 - $78.92 $208 Million - $230 Million	-2,920,000 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$64.88 - $75.68 $71.4 Million - $83.2 Million	1,100,000 Added 60.44%	2,920,000 $207 Million
Q1 2018 May 15, 2018	BUY	$72.84 - $88.8 $133 Million - $162 Million	1,820,000 New	1,820,000 $137 Million
Q4 2017 Feb 14, 2018	SELL	$71.15 - $83.52 $67.2 Million - $78.9 Million	-945,000 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$72.11 - $85.47 $68.1 Million - $80.8 Million	945,000	945,000 $76.6 Million

1,926

992M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Farallon Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Farallon Capital Management LLC with notifications on news.